Sporegen

Executive Summary

Sporegen is a UK-based biotechnology company founded in 2018 that specializes in developing Bacillus-based applications for vaccines, drug delivery, and probiotics. The company leverages the unique properties of bacterial spores to create heat-stable mucosal vaccines, targeted cancer therapies, and novel food ingredients. By harnessing the natural resilience and stability of spores, Sporegen aims to address key challenges in biopharma, including cold-chain dependency in vaccine distribution and targeted delivery of therapeutics. The company's platform technology has potential applications across multiple high-growth markets, positioning it as a versatile player in the biotech landscape. Despite its innovative approach, Sporegen remains in early stages with limited public information on funding, partnerships, or clinical progress. The company has not disclosed total raised or valuation, suggesting it may still be in seed or early Series A phase. Its success hinges on advancing lead candidates into preclinical or clinical development, securing strategic partnerships, and demonstrating proof-of-concept in vivo. The competitive landscape includes other spore-based platform companies, but Sporegen's exclusive focus on Bacillus and broad application scope could differentiate it. Near-term catalysts would likely involve milestones such as IND filings, partnerships, or financing rounds.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead heat-stable mucosal vaccine candidate40% success
• Q3 2026Strategic partnership for Bacillus drug delivery platform30% success
• Q2 2026Series A funding round closure50% success